Byron Elton has served as our director since December 16, 2022 and our President and CEO since February 1, 2024. Mr. Elton is an experienced media and marketing executive with a proven record in pioneering new business development strategies and building top-flight marketing organizations. Since June 2018, he has been President of Elton Enterprises, Inc., which is involved in the wellness, fitness and health sectors. Mr. Elton is also the owner of certain StretchLab franchises. He is a co-founder since June 2017 of Pardue Associates, operating monsho, a brand-centric, creative communications agency focused on delivering results. From 2013 to 2017, Mr. Elton was a partner of Clear Search, an executive search firm. Prior to that, from 2009 until 2013, Mr. Elton served as President and Chief Executive Officer of Carbon Sciences, Inc., a cleantech company developing a technology to convert earth destroying carbon dioxide into a useful form. Mr. Elton previously served as Senior Vice President of Sales for Univision Online from 2007 to 2008. Mr. Elton also served for eight years as an executive at AOL Media Networks from 2000 to 2007, where his assignments included Regional Vice President of Sales for AOL and Senior Vice President of E-Commerce for AOL Canada. His broadcast media experience includes leading the ABC affiliate in Santa Barbara, California from 1995 to 2000 and the CBS affiliate in Monterrey, California from 1998 to 1999, in addition to serving as President of the Alaskan Television Network from 1995 to 1999. Mr. Elton studied Advertising and Marketing Communications at Brigham Young University.

Expert in the discovery, development, and translation of novel therapies across diverse therapeutic modalities Part of teams that developed the first-in-human drug candidates, including small molecule STING agonists and personalized cancer neoantigen vaccine Co-authored more than 16 scientific papers and inventor on 3 issued U.S. patents and multiple pending applications Formerly Director of Discovery Biology at RAPT Therapeutics Formerly Senior Scientist and Head of Biochemistry at Aduro Biotech B.S. in Plant Sciences from the University of California, Santa Cruz PhD in Molecular and Cell Biology from the University of California, Berkeley"

An inventor of the Company’s Universal Cancer Treatment platform. Expert computational biologist using next generation sequencing data to identify new drug targets and biomarkers of response to cancer therapeutics/ Formerly Bioinformatician at Xenter Medical Technologies/Formerly Computational Scientist at RAPT Therapeutics. Invented software to improve cancer antigen detection. Invented a gene-signature approach to select treatment for breast cancer. Received his B.S in Bioinformatics from Brigham Young University. Received his PhD in Cancer Biology with an emphasis in Bioinformatics from the University of Arizona

Sumant Ramachandra serves as an Independent Director on the Board of Lyell Immunopharma (“Lyell”), following Lyell’s acquisition of ImmPACT Bio (“ImmPACT”) in October 2024. As CEO of ImmPACT from November 2021 until its acquisition, he led capital raises, secured clinical grants, and built a team that achieved FDA clearance for three Investigational New Drug (IND) applications, established manufacturing capabilities, and advanced multiple clinical studies. In addition, Dr. Ramachandra currently serves as an advisor to private equity funds on companies in the pharmaceuticals, biotechnology, and medical devices/software spaces. Previously, Dr. Ramachandra served as Chief Science, Technology, and Medical Officer at Baxter International, starting in June 2017. He was also appointed President of Baxter Pharmaceuticals in 2019. Prior to Baxter, he held the role of Senior Vice President, Head of Research & Development, at Pfizer Essential Health, and served as Chief Scientific Officer at Hospira from 2008 until Pfizer acquired Hospira in 2015. Earlier in his career, Dr. Ramachandra held senior roles at Pfizer and Merck & Co., specializing in oncology, global product development, medical affairs, business development, and clinical pharmacology. He began his medical career as an intern and resident physician at Massachusetts General Hospital, Harvard Medical School. Dr. Ramachandra earned his undergraduate degree in biochemistry, a PhD in experimental pathology (with a focus on chronic lymphocytic leukemia), and an MD from Rutgers University. He also holds an MBA from the Wharton School, University of Pennsylvania.